Immediate Impact
54 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Hepatocellular carcinoma: signaling pathways and therapeutic advances
2025 Standout
Works of Linna Wang being referenced
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
2020 Standout
A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Linna Wang | 560 | 269 | 376 | 32 | 1.1k | |
| Jiasheng Zheng | 257 | 180 | 305 | 54 | 978 | |
| Zheng Wang | 395 | 146 | 292 | 39 | 1.3k | |
| Yihong Ling | 339 | 190 | 335 | 56 | 1.1k | |
| Meihua Wang | 398 | 263 | 148 | 38 | 1.3k | |
| Yong Li | 246 | 140 | 247 | 49 | 921 | |
| Weijian Guo | 573 | 561 | 149 | 70 | 1.3k | |
| Arsen Mikaelyan | 293 | 140 | 479 | 26 | 1.4k | |
| Dirk Uhlmann | 377 | 293 | 274 | 42 | 1.2k | |
| Rajendra Ramsamooj | 225 | 148 | 151 | 31 | 912 | |
| Tong‐Chun Xue | 490 | 172 | 382 | 40 | 1.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...